Molecule
Isosulfan blue is a prescription medicine. It is available as injection for subcutaneous use. MedsAcross supplies Isosulfan blue for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Isosulfan blue injection upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities, chyluria, chylous ascites or chylothorax, lymph node involvement by primary or secondary neoplasm, lymph node response to therapeutic modalities.
Source: US FDA prescribing information
Isosulfan blue injection is to be administered subcutaneously, one-half (1/2) mL into three interdigital spaces of each extremity per study. A maximum dose of 3 mL (30 mg) isosulfan blue is, therefore, injected.
Source: US FDA prescribing information
Isosulfan blue injection is contraindicated in those individuals with known hypersensitivity to triphenylmethane or related compounds. Hypersensitivity to triphenylmethane or related compounds.
Source: US FDA prescribing information
Life threatening anaphylactic reactions have occurred after isosulfan blue injection administration. Monitor patients closely for at least 60 minutes after administration of isosulfan blue injection. The admixture of isosulfan blue injection with local anesthetics results in an immediate precipitation of 4% to 9% drug complex. Use a separate syringe for anesthetics. Isosulfan blue injection interferes with measurements in peripheral blood pulse oximetry. Arterial blood gas analysis may be needed.
Source: US FDA prescribing information
Hypersensitivity Reactions: Hypersensitivity reactions occur in approximately 2% of patients and include life threatening anaphylactic reactions with respiratory distress, shock, angioedema, urticaria, pruritus. A death has been reported following IV administration of a similar compound.
Source: US FDA prescribing information
No drug interactions have been identified with isosulfan blue injection. No drug interactions have been identified for isosulfan blue injection.
Source: US FDA prescribing information
Vials should be stored at 20° to 25°C (68° to 77°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Isosulfan blue, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Isosulfan blue 50 mg/5 mL injectionSubcutaneousGeneric name | — | US FDA | Available on request |
| Isosulfan blue 10 mg/1 mL injectionSubcutaneousGeneric name | — | US FDA | Available on request |
| Isosulfan blue 30 mg/3 mL injectionSubcutaneousGeneric name | — | US FDA | Available on request |
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 29 July 1981 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 3 presentations of Isosulfan blue and sources them for licensed hospitals, importers and physicians against valid import documents.
Yes. The US FDA first approved Isosulfan blue on 29 July 1981, according to Drugs@FDA.
No listed presentation of Isosulfan blue is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.